Urogen Pharma (NASDAQ:URGN) Receives Average Recommendation of “Moderate Buy” from Analysts

Urogen Pharma (NASDAQ:URGN) has been assigned an average rating of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $41.6250.

A number of analysts recently weighed in on URGN shares. LADENBURG THALM/SH SH started coverage on shares of Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. Oppenheimer lifted their price objective on Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. Finally, UBS Group restated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th.

Urogen Pharma Price Performance

Urogen Pharma stock opened at $38.24 on Wednesday. Urogen Pharma has a fifty-two week low of $15.86 and a fifty-two week high of $43.93. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -13.91 and a beta of 1.57. The firm has a fifty day moving average price of $34.98 and a two-hundred day moving average price of $26.33.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. As a group, sell-side analysts expect that Urogen Pharma will post -0.76 earnings per share for the current year.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the insider directly owned 119,763 shares in the company, valued at $4,790,520. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,222 shares of company stock valued at $892,661 in the last quarter. Corporate insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after purchasing an additional 1,653 shares during the last quarter. Main Street Financial Solutions LLC boosted its position in Urogen Pharma by 8.2% in the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock valued at $356,000 after buying an additional 1,968 shares in the last quarter. Barclays PLC boosted its position in Urogen Pharma by 3.8% in the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock valued at $1,352,000 after buying an additional 2,125 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its position in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.